Genetic testing to provide targeted treatment for cystic fibrosis patients

Pharmacogenomics

Volumn 8, Issue 9, 2007, Pages 1101-1104

  Edelman, Aleksander ^a,b   Sermet Gaudelus, Isabelle ^b,c   Rousset, Jean Pierre ^d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; GENTAMICIN; MESSENGER RNA; NEGAMYCIN; PTC 124; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

CHLORIDE TRANSPORT; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; GENE REPRESSION; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; NONHUMAN; NONSENSE MUTATION; PHARMACOGENETICS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SODIUM TRANSPORT; STOP CODON; TRANSLATION REGULATION; UNSPECIFIED SIDE EFFECT;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE THERAPY; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; PEPTIDE CHAIN TERMINATION, TRANSLATIONAL;

EID: 35348926322     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.9.1101     Document Type: Editorial

References (18)

1. Schmitz A, Famulok M: Chemical biology: ignore the nonsense. Nature 447(7140), 42-43 (2007).
2. Linde L, Boelz S, Nissim-Rafinia M et al.: Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J. Clin. Invest. 117(3), 683-692 (2007).
3. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE: Nonsense-mediated decay approaches the clinic. Nat. Genet. 36(8), 801-808 (2004).
4. Rowe SM, Miller S, Sorscher EJ: Cystic fibrosis. N. Engl. J. Med. 352(19), 1992-2001 (2005).
5. Ollero M, Brouillard F, Edelman A: Cystic fibrosis enters the proteomics scene: new answers to old questions. Proteomics 6(14), 4084-4099 (2006).
6. Davezac N, Tondelier D, Lipecka J et al.: Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/ deltaF508-CFTR to the plasma membrane. Proteomics 4(12), 3833-3844 (2004).
7. Sermet-Gaudelus I, Renouil M, Fajac A et al.: In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 5, 5 (2007).
8. Kerem E: Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10(6), 547-552 (2004).
9. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2(4), 467-469 (1996).
10. Manuvakhova M, Keeling K, Bedwell DM: Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6(7), 1044-1055 (2000).
11. Welch EM, Barton ER, Zhuo J et al.: PTC124 targets-genetic disorders caused by nonsense mutations. Nature 447 (7140), 87-91 (2007).
12. Namy O, Hatin I, Rousset JP: Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep. 2(9), 787-793 (2001).
13. Clancy JP, Bebok Z, Rutz F et al.: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163(7), 1683-1692 (2001).
14. Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, Rousset JP: Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther. 11(7), 619-627 (2004).
15. Bedwell DM, Kaenjak A, Benos DJ et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 3(11), 1280-1284 (1997).
16. -/- mouse carrying a human CFTR-G542X transgene. J. Mol. Med. 80(9), 595-604 (2002).
17. Wilschanski M, Yahav Y, Yaacov Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349(15), 1433-1441 (2003).
18. Clancy JP, Rowe SM, Bebok Z et al.: No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am. J. Respir. Cell Mol. Biol. (2007).